Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Abstract Background The purpose of this study was to evaluate the efficacy of denosumab or zoledronic acid (ZA) using symptomatic skeletal events (SSEs) as the primary endpoint in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer. Methods Asian postmenopausal women w...

Full description

Bibliographic Details
Main Authors: Chi Zhang, Fan Zhang, Guanzhao Liang, Xianshang Zeng, Weiguang Yu, Zhidao Jiang, Jie Ma, Mingdong Zhao, Min Xiong, Keke Gui, Fenglai Yuan, Weiping Ji
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Musculoskeletal Disorders
Subjects:
Denosumab
Zoledronic acid
Breast cancer
Symptomatic skeletal event
Outcome analyses
Online Access:http://link.springer.com/article/10.1186/s12891-018-2338-6

Internet

http://link.springer.com/article/10.1186/s12891-018-2338-6

Similar Items